Drug intelligence / Profile preview

E2.3

Development stage: Phase 1
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Monoclonal antibody E2.3 is an antitransferrin receptor antibody under investigation for the treatment of advanced cancer. It is designed to selectively target tumor cells by binding to the transferrin receptor, thereby either directly inducing cell death or facilitating the delivery of cytotoxic agents to these cells, while minimizing harm to healthy tissues.

Targets

TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on E2.3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E2.3.

Explore the full profile